Karyopharm announces preliminary unaudited fourth quarter and full year 2021 net product revenues and outlines 2022 objectives

Newton, mass., jan. 10, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for xpovio, the company's first-in-class, oral xpo1 inhibitor, and outlined its 2021 achievements and 2022 objectives.
KPTI Ratings Summary
KPTI Quant Ranking